Vivimed Labs has launched Favulous, its generic version of Covid-19 drug Favipiravir Tablet 200 mg and 400 mg in India.

The launch follows the approval secured by the Hyderabad-based specialty chemicals and pharma company secured approval from the Indian Director General of Health Services (DGHS) for manufacturing and marketing Favipiravir.

Vivimed Labs said that it will closely work with the various governments and medical community in India for ensuring the availability of Favulous.

Favipiravir is an oral anti-viral treatment, which has approvals in various countries for the potential treatment of Covid-19 in patients having mild to moderate disease.

Ramesh Krishnamurthy – CEO of Vivimed Labs said: “With huge spike in Covid19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals.

“We are launching “Favulous” at a competitive price to make the drug accessible to more and more patients thereby ensuring good health and reducing their financial burden. This is in line with Vivimed’s commitment to be at forefront in India’s fight against Covid-19.”

  Coronavirus, COVID-19, FabiFlu, favipiravir, Favulous, Hyderabad, India, Ramesh Krishnamurthy, Vivimed Labs